Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-143
Last updated

Report documents

  1. Extract of dossier assessment

    Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 688 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-143_en
    Download file : Extract of dossier assessment (PDF document, 688 kB, EN, not accessible)

  2. Dossier assessment

    Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 3 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-143
    Download file : Dossier assessment (PDF document, 3 MB, DE, not accessible)

Dossier assessment

Indication:

Adult patients with mismatch repair deficient / microsatellite instability‑high primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy

Result of dossier assessment:
  • Patients with primary FIGO stage III: hint of lesser benefit
  • Patients with primary FIGO stage IV or recurrent: indication of major added benefit

Additional information

Federal Joint Committee (G-BA)

2024-06-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-143
Commission
Commission awarded on 21.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-143_en

Connected Projects

  1. Dossier assessment

    Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-84
    Last updated

    Status: Commission completed

  2. Addendum

    Dostarlimab (endometrial cancer) - Addendum to Project A23-143

    Project no.
    A24-59
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Dostarlimab (endometrial cancer, pMMR) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-24
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page